Cargando…

Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma

Background: Tyrosine kinase inhibitors (TKIs) prolong progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC), some of which may achieve long-term responses. Herein, we report clinical and pathological characteristics of patients who achieved long-term responses durin...

Descripción completa

Detalles Bibliográficos
Autores principales: Catalano, Martina, De Giorgi, Ugo, Maruzzo, Marco, Bimbatti, Davide, Buti, Sebastiano, Mazzaschi, Giulia, Procopio, Giuseppe, Santoni, Matteo, Galli, Luca, Conca, Raffaele, Doni, Laura, Antonuzzo, Lorenzo, Roviello, Giandomenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599295/
https://www.ncbi.nlm.nih.gov/pubmed/36289706
http://dx.doi.org/10.3390/biomedicines10102444
_version_ 1784816559721545728
author Catalano, Martina
De Giorgi, Ugo
Maruzzo, Marco
Bimbatti, Davide
Buti, Sebastiano
Mazzaschi, Giulia
Procopio, Giuseppe
Santoni, Matteo
Galli, Luca
Conca, Raffaele
Doni, Laura
Antonuzzo, Lorenzo
Roviello, Giandomenico
author_facet Catalano, Martina
De Giorgi, Ugo
Maruzzo, Marco
Bimbatti, Davide
Buti, Sebastiano
Mazzaschi, Giulia
Procopio, Giuseppe
Santoni, Matteo
Galli, Luca
Conca, Raffaele
Doni, Laura
Antonuzzo, Lorenzo
Roviello, Giandomenico
author_sort Catalano, Martina
collection PubMed
description Background: Tyrosine kinase inhibitors (TKIs) prolong progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC), some of which may achieve long-term responses. Herein, we report clinical and pathological characteristics of patients who achieved long-term responses during first-line TKI treatment. Methods: Patients receiving TKI as first-line therapy from January 2010 to December 2017 in seven Italian Oncology Centers were reviewed. Sixty-six patients were considered as long-term responders, as they remained progression-free for 36 months or more during TKI treatment. A logistic regression model was performed to evaluate the effect of each clinical-pathological variable on the probability of responding long-term. Results: A total of 335 patients with a median age of 66 years were included in the analysis. The median PFS and overall survival among the long-term responders was 70 and 106 months, respectively. At a landmark PFS analysis performed 36 months after the start of treatment, the median PFS was 34 months. Multivariate analysis from all patients identified previous nephrectomy, Eastern Cooperative Oncology Group Performance Status (ECOG PS) < 1, and lack of liver metastasis as favorable prognostic factors for long-term response. Female gender and lack of liver metastasis positively correlated with long-term responses in favorable-risk-score population, as well as ECOG PS < 1 in intermediate-poor risk score population. Patients Summary: Previous surgery, clinical condition, and lack of liver metastasis may predict long-term responses to tyrosine kinase inhibitors. Conclusions: TKIs can lead to a long-term response in a subset of patients with metastatic RCC. Previous nephrectomy, optimal performance status (ECOG PS = 0), and lack of liver metastasis may predict long-term responses.
format Online
Article
Text
id pubmed-9599295
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95992952022-10-27 Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma Catalano, Martina De Giorgi, Ugo Maruzzo, Marco Bimbatti, Davide Buti, Sebastiano Mazzaschi, Giulia Procopio, Giuseppe Santoni, Matteo Galli, Luca Conca, Raffaele Doni, Laura Antonuzzo, Lorenzo Roviello, Giandomenico Biomedicines Article Background: Tyrosine kinase inhibitors (TKIs) prolong progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC), some of which may achieve long-term responses. Herein, we report clinical and pathological characteristics of patients who achieved long-term responses during first-line TKI treatment. Methods: Patients receiving TKI as first-line therapy from January 2010 to December 2017 in seven Italian Oncology Centers were reviewed. Sixty-six patients were considered as long-term responders, as they remained progression-free for 36 months or more during TKI treatment. A logistic regression model was performed to evaluate the effect of each clinical-pathological variable on the probability of responding long-term. Results: A total of 335 patients with a median age of 66 years were included in the analysis. The median PFS and overall survival among the long-term responders was 70 and 106 months, respectively. At a landmark PFS analysis performed 36 months after the start of treatment, the median PFS was 34 months. Multivariate analysis from all patients identified previous nephrectomy, Eastern Cooperative Oncology Group Performance Status (ECOG PS) < 1, and lack of liver metastasis as favorable prognostic factors for long-term response. Female gender and lack of liver metastasis positively correlated with long-term responses in favorable-risk-score population, as well as ECOG PS < 1 in intermediate-poor risk score population. Patients Summary: Previous surgery, clinical condition, and lack of liver metastasis may predict long-term responses to tyrosine kinase inhibitors. Conclusions: TKIs can lead to a long-term response in a subset of patients with metastatic RCC. Previous nephrectomy, optimal performance status (ECOG PS = 0), and lack of liver metastasis may predict long-term responses. MDPI 2022-09-30 /pmc/articles/PMC9599295/ /pubmed/36289706 http://dx.doi.org/10.3390/biomedicines10102444 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Catalano, Martina
De Giorgi, Ugo
Maruzzo, Marco
Bimbatti, Davide
Buti, Sebastiano
Mazzaschi, Giulia
Procopio, Giuseppe
Santoni, Matteo
Galli, Luca
Conca, Raffaele
Doni, Laura
Antonuzzo, Lorenzo
Roviello, Giandomenico
Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
title Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
title_full Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
title_fullStr Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
title_full_unstemmed Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
title_short Long-Term Response to Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
title_sort long-term response to tyrosine kinase inhibitors for metastatic renal cell carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9599295/
https://www.ncbi.nlm.nih.gov/pubmed/36289706
http://dx.doi.org/10.3390/biomedicines10102444
work_keys_str_mv AT catalanomartina longtermresponsetotyrosinekinaseinhibitorsformetastaticrenalcellcarcinoma
AT degiorgiugo longtermresponsetotyrosinekinaseinhibitorsformetastaticrenalcellcarcinoma
AT maruzzomarco longtermresponsetotyrosinekinaseinhibitorsformetastaticrenalcellcarcinoma
AT bimbattidavide longtermresponsetotyrosinekinaseinhibitorsformetastaticrenalcellcarcinoma
AT butisebastiano longtermresponsetotyrosinekinaseinhibitorsformetastaticrenalcellcarcinoma
AT mazzaschigiulia longtermresponsetotyrosinekinaseinhibitorsformetastaticrenalcellcarcinoma
AT procopiogiuseppe longtermresponsetotyrosinekinaseinhibitorsformetastaticrenalcellcarcinoma
AT santonimatteo longtermresponsetotyrosinekinaseinhibitorsformetastaticrenalcellcarcinoma
AT galliluca longtermresponsetotyrosinekinaseinhibitorsformetastaticrenalcellcarcinoma
AT concaraffaele longtermresponsetotyrosinekinaseinhibitorsformetastaticrenalcellcarcinoma
AT donilaura longtermresponsetotyrosinekinaseinhibitorsformetastaticrenalcellcarcinoma
AT antonuzzolorenzo longtermresponsetotyrosinekinaseinhibitorsformetastaticrenalcellcarcinoma
AT roviellogiandomenico longtermresponsetotyrosinekinaseinhibitorsformetastaticrenalcellcarcinoma